Literature DB >> 22087188

Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence.

Peter Higgs1, Rachel Sacks-Davis, Judy Gold, Margaret Hellard.   

Abstract

BACKGROUND: Alcohol consumption, current injecting drug use, and pre-existing mental illness have been identified as 3 of the main reasons for excluding patients from treatment for hepatitis C.
OBJECTIVES: We reviewed the literature to obtain an evidence base for these common exclusion criteria.
MATERIALS AND METHODS: We reviewed original research and meta-analyses investigating the effects of alcohol consumption, current injecting drug use, and pre-existing mental illness.
RESULTS: We identified 66 study reports relevant to the review, but found only limited evidence to support withholding of treatment on the basis of the 3 previously mentioned exclusion criteria.
CONCLUSIONS: Currently, there is a lack of evidence for many of the barriers faced by patients in availing treatment for hepatitis C. Adherence to treat routine was found to be a better predictor of sustained virological response than injecting drug or alcohol consumption during treatment period or the presence of a pre-existing mental disorder. Although several challenges remain, we need to ensure that treatment decisions are based on the best available evidence and the treatment is performed appropriately on a case-by-case basis.

Entities:  

Keywords:  Alcohol; Drug users; Hepatitis C virus; Interferon; Mental disorder

Year:  2011        PMID: 22087188      PMCID: PMC3212767     

Source DB:  PubMed          Journal:  Hepat Mon        ISSN: 1735-143X            Impact factor:   0.660


  68 in total

1.  Triggering of acute alcoholic hepatitis by alpha-interferon therapy.

Authors:  H Zylberberg; H Fontaine; V Thépot; B Nalpas; C Bréchot; S Pol
Journal:  J Hepatol       Date:  1999-04       Impact factor: 25.083

2.  Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?

Authors:  Karen H Seal; Sue L Currie; Hui Shen; Bhupinderjit S Anand; Edmund J Bini; Norbert Brau; Lennox Jeffers; Teresa L Wright
Journal:  J Clin Gastroenterol       Date:  2007-02       Impact factor: 3.062

3.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

4.  Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Authors:  Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

Review 5.  Hepatitis C and alcohol: interactions, outcomes, and implications.

Authors:  Renuka Bhattacharya; Margaret C Shuhart
Journal:  J Clin Gastroenterol       Date:  2003-03       Impact factor: 3.062

6.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

7.  Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.

Authors:  Alain H Litwin; Kenneth A Harris; Shadi Nahvi; Philippe J Zamor; Irene J Soloway; Peter L Tenore; Daniel Kaswan; Marc N Gourevitch; Julia H Arnsten
Journal:  J Subst Abuse Treat       Date:  2008-11-28

8.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

9.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users.

Authors:  Markus Backmund; Kirsten Meyer; Brian R Edlin
Journal:  Clin Infect Dis       Date:  2004-10-26       Impact factor: 9.079

10.  Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam.

Authors:  Thijs J W van de Laar; Richard Molenkamp; Charlotte van den Berg; Janke Schinkel; Marcel G H M Beld; Maria Prins; Roel A Coutinho; Sylvia M Bruisten
Journal:  J Hepatol       Date:  2009-06-18       Impact factor: 25.083

View more
  7 in total

1.  Use of health care services by people with substance use disorders in Belgium: a register-based cohort study.

Authors:  Luk Van Baelen; Els Plettinckx; Jérôme Antoine; Karin De Ridder; Brecht Devleesschauwer; Lies Gremeaux
Journal:  Arch Public Health       Date:  2021-06-23

2.  Reasons for Nonattendance across the Hepatitis C Disease Course.

Authors:  Gail Butt; Liza McGuinness; Terri Buller-Taylor; Sandi Mitchell
Journal:  ISRN Nurs       Date:  2013-09-11

3.  The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.

Authors:  Edward R Cachay; Lucas Hill; David Wyles; Bradford Colwell; Craig Ballard; Francesca Torriani; William C Mathews
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

4.  Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients.

Authors:  S Mantravadi
Journal:  Health Equity       Date:  2017-09-01

5.  Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey.

Authors:  Luk Van Baelen; Els Plettinckx; Jérôme Antoine; Lies Gremeaux
Journal:  Harm Reduct J       Date:  2020-02-21

Review 6.  Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.

Authors:  Xue Yang; Yang Tang; Di Xu; Guang Zhang; Peng Xu; Houlin Tang; Lin Pang
Journal:  Virol J       Date:  2021-07-27       Impact factor: 4.099

7.  Misinformation About COVID-19 in Sub-Saharan Africa: Evidence from a Cross-Sectional Survey.

Authors:  Uchechukwu L Osuagwu; Chundung A Miner; Dipesh Bhattarai; Khathutshelo Percy Mashige; Richard Oloruntoba; Emmanuel Kwasi Abu; Bernadine Ekpenyong; Timothy G Chikasirimobi; Piwuna Christopher Goson; Godwin O Ovenseri-Ogbomo; Raymond Langsi; Deborah Donald Charwe; Tanko Ishaya; Obinna Nwaeze; Kingsley Emwinyore Agho
Journal:  Health Secur       Date:  2021 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.